GKSL Submits Investor Presentation, Hints at Potential IPO
Gujarat Kidney And Super Speciality Limited (GKSL) released its Q2 FY27 investor presentation. The company reported a 195% YoY increase in revenue to ₹3,809 Lakhs and a 129% YoY rise in PAT to ₹660 Lakhs. GKSL is also exploring a potential IPO, having submitted a Draft Red Herring Prospectus.
The submission of an investor presentation with strong financial results and the disclosure of a potential IPO are significant events that can impact investor interest and the company's valuation.
The company's financial performance shows strong year-over-year growth in revenue and profits, and the mention of a potential IPO indicates positive future outlook and growth plans.
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted an investor presentation, dated November 4, 2026, for the quarter and half-year ended September 30, 2026. This presentation includes detailed financial highlights for Q2 FY27 and H1 FY27, showcasing significant year-over-year growth in revenue, EBITDA, and PAT.
Key financial metrics for Q2 FY27 reveal revenue from operations at ₹3,809 Lakhs, a 195% YoY increase. EBITDA stood at ₹1,022 Lakhs with a 26.8% margin, up 240 bps QoQ, and PAT was ₹660 Lakhs, up 129% YoY with a 17.3% margin. For H1 FY27, revenue reached ₹7,238 Lakhs, a 157% YoY increase, with EBITDA at ₹1,859 Lakhs and PAT at ₹1,192 Lakhs.
The presentation also mentions the company's strategic positioning, focusing on building a scalable, specialist-led healthcare platform across central Gujarat. It highlights an asset-light business model, expansion through acquisitions, and a focus on clinical specialization. GKSL is contemplating a potential Initial Public Offering (IPO) and has submitted a Draft Red Herring Prospectus to the BSE and NSE.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.